Cargando…

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

TRIAL REGISTRY: Clinicaltrials.gov #NCT01180959. BACKGROUND: Early clinical studies of bevacizumab and erlotinib in advanced hepatocellular carcinoma (HCC) have a tolerable toxicity and a promising clinical outcome. We evaluated the efficacy and tolerability of this combination as a second-line ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaseb, Ahmed O, Morris, Jeffrey S, Iwasaki, Michiko, Al-Shamsi, Humaid O, Raghav, Kanwal Pratap Singh, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Elsayes, Khaled M, Xiao, Lianchun, Abdel-Wahab, Reham, Shalaby, Ahmed S, Hassan, Manal, Hassabo, Hesham M, Wolff, Robert A, Yao, James C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760665/ https://www.ncbi.nlm.nih.gov/pubmed/26929648 http://dx.doi.org/10.2147/OTT.S91977

Ejemplares similares

Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma
por: Mahvash, Armeen, et al.
Publicado: (2016)

Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
por: Kaseb, Ahmed O., et al.
Publicado: (2014)

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
por: Mohamed, Yehia I., et al.
Publicado: (2022)

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018)

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2016)

The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab
por: Awiwi, Muhammad O, et al.
Publicado: (2022)

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
por: Lacin, Sahin, et al.
Publicado: (2020)

Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance
por: Khalaf, Ahmed M, et al.
Publicado: (2018)

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?
por: Ali, Mahmoud A, et al.
Publicado: (2017)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
por: Hsu, Chiun, et al.
Publicado: (2021)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer
por: Chadha, Awalpreet S., et al.
Publicado: (2016)

Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
por: Villalobos, Matthias, et al.
Publicado: (2019)

Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development
por: Haque, Abedul, et al.
Publicado: (2022)

Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
por: Tomar, Shubham, et al.
Publicado: (2022)

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Mohamed, Yehia I., et al.
Publicado: (2021)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017)

The State of Cancer Care in the United Arab Emirates in 2022
por: Al-Shamsi, Humaid O.
Publicado: (2022)

Barriers and Facilitators to Conducting Oncology Clinical Trials in the UAE
por: Al-Shamsi, Humaid O.
Publicado: (2022)

The Perception and Awareness of the Public about Cancer and Cancer Screening in the United Arab Emirates, a Population-Based Survey
por: Humaid Al-Shamsi, Sarah, et al.
Publicado: (2023)

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma
por: Kaseb, Ahmed O., et al.
Publicado: (2022)

Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy
por: Yasui, Hirotoshi, et al.
Publicado: (2014)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ruijian, et al.
Publicado: (2023)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging
por: Moawad, Ahmed W, et al.
Publicado: (2020)

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma
por: Niekamp, Andrew, et al.
Publicado: (2018)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
por: Yavuz, Betul Gok, et al.
Publicado: (2020)

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials
por: Deng, Wusheng, et al.
Publicado: (2022)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
por: Fukuhara, Tatsuro, et al.
Publicado: (2020)

A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma
por: El-Khouly, Fatma E., et al.
Publicado: (2021)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8d1l7fsrcdf62cdcbo9snmmgif